



***UPDATED WITH NEW TIME**:** Veracyte to Present at the 2018 UBS Global Healthcare Conference

May 9, 2018

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 9, 2018-- [Veracyte, Inc.](#) (Nasdaq: VCYT) today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the 2018 UBS Global Healthcare Conference on Wednesday, May 23, 2018 at 9:00 a.m. Eastern Time in New York, NY.

The live webcast of the presentation and a subsequent replay may be accessed by visiting Veracyte's website at <http://investor.veracyte.com>. The replay of the webcast will be available shortly after the conclusion of the presentation and archived on the company's website for 90 days following the presentation.

About Veracyte

Veracyte (Nasdaq: VCYT) is a leading genomic diagnostics company that is providing trustworthy and actionable answers that fundamentally improve patient care when current diagnostic tests are uncertain. The company's products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a \$2 billion market opportunity. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc.



View source version on businesswire.com: <https://www.businesswire.com/news/home/20180509006550/en/>

Source: Veracyte, Inc.

Veracyte, Inc.

Media:

Tracy Morris, 650-380-4413

tracy.morris@veracyte.com

or

Investors:

Keith Kennedy, 650-243-6357

Chief Financial Officer

keith@veracyte.com